NuPathe Inc. · Conshohocken, PA United States (NASDAQ: PATH)
| 227 Washington St., Ste. 200 | Phone: 484-567-0130 |
| Conshohocken, PA | Fax: 484-567-0136 |
| 19428 | |
| United States |
NuPathe Inc. Rankings
Company Description
NuPathe hopes to find a new route to neuro relief, and profits. The drug company, which focuses on neurological and psychiatric treatments, has several candidates in its pipeline. The most advanced is Zelrix, a single-use patch for treating migraines. Since migraine sufferers experience nausea that makes it difficult to take oral medications, the company believes there is a large market for a transdermal treatment. Also in NuPathe's R&D pipeline are drugs for Parkinson's disease and for schizophrenia and bipolar disorder, both in the preclinical stage. The company plans to hire sales, marketing, and distribution staff once Zelrix is approved. NuPathe was formed in 2005 and filed to go public in 2010.
Financials
| Company Type | Public - NASDAQ: PATH Single Location |
|---|---|
| Fiscal Year-End | December |
| 2010 Employees | 26 |
Executives
21 executives listed for NuPathe Inc.'s Conshohocken, PA location.
| Chairman | Michael Cola | |
|---|---|---|
| CEO and Director | Jane Hollingsworth | |
| President | Terri Sebree |


